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Monoamine oxidase type B inhibitors in early Parkinson’s disease:
meta-analysis of 17 randomised trials involving 3525 patients
Natalie J Ives, Rebecca L Stowe, Joanna Marro, Carl Counsell, Angus Macleod, Carl E Clarke, Richard Gray, Keith
Wheatley
Abstract
Objective To quantify more reliably the benefits and risks of
monoamine oxidase type B inhibitors (MAOBIs) in early
Parkinson’s disease.
Data sources Searches of the Cochrane Library, Medline,
Embase, PubMed, and Web of Science for years 1966-2003, plus
major journals in the field, abstract books, and proceedings of
meetings, for randomised trials comparing MAOBIs with
placebo or levodopa.
Data extraction Available data on mortality, motor
complications, side effects, treatment compliance, and clinician
rated disability (for example, unified Parkinson’s disease rating
scale) were extracted from 17 trials and combined using
standard meta-analytic methods.
Results No significant difference in mortality existed between
patients on MAOBIs and control patients (odds ratio 1.13, 95%
confidence interval 0.94 to 1.34; P = 0.2). Patients randomised
to MAOBIs had significantly better total scores, motor scores,
and activities of daily living scores on the unified Parkinson’s
disease rating scale at three months compared with patients
taking placebo; they were also less likely to need additional
levodopa (0.57, 0.48 to 0.67; P < 0.00001) or to develop motor
fluctuations (0.75, 0.59 to 0.95; P = 0.02). No difference existed
between the two groups in the incidence of side effects or
withdrawal of patients.
Conclusions MAOBIs reduce disability, the need for levodopa,
and the incidence of motor fluctuations, without substantial side
effects or increased mortality. However, because few trials have
compared MAOBIs with other antiparkinsonian drugs,
uncertainty remains about the relative benefits and risks of
MAOBIs. Further large, long term comparative trials that
include patient rated quality of life measures are needed.
Introduction
Clinical decline in Parkinson’s disease results from degeneration
of nigrostriatal dopaminergic neurones. This process may be
mediated by oxidative free radicals, which in animal models of
Parkinson’s disease can be inhibited by monoamine oxidase type
B inhibitors (MAOBIs), such as selegiline.1 Consequently,
selegiline has been used either alone or in addition to levodopa
in both early and later Parkinson’s disease in the hope that it may
slow disease progression. Clinical trials in the 1980s, such as the
DATATOP study,2 suggested that selegiline might have a neuro-
protective effect, but this remains controversial.3 Further
uncertainty about MAOBIs arose in 1995, when a study by the
Parkinson’s Disease Research Group of the United Kingdom
(UK-PDRG) closed its selegiline arm after finding 57% higher
mortality in patients receiving combined selegiline and levodopa
treatment compared with patients on levodopa alone.4 Other
randomised trials have, however, failed to show any increase in
mortality.5 6
To clarify the role of MAOBIs, we did a meta-analysis of data
from all published trials comparing any MAOBI with either
levodopa or placebo in early Parkinson’s disease. Meta-analyses
give a more accurate view of the randomised evidence, because
they include more patients than does any single trial, so random
errors are smaller. Also, by reviewing data from all relevant trials,
a more balanced assessment is obtained.
Methods
Identification of trials
We systematically searched the literature from 1966 to
December 2003 to identify randomised trials of MAOBIs in early
Parkinson’s disease, using the search strategy recommended by
the Cochrane Collaboration.7 This involved searching electronic
databases including the Cochrane Library, Medline, Embase,
PubMed, andWeb of Science and hand searching major journals
in the field, abstract books, conference proceedings, and
reference lists of retrieved publications.
Inclusion criteria
Eligible studies had to be randomised trials in early Parkinson’s
disease comparing an MAOBI (selegiline, lazabemide, or
rasagiline), with or without levodopa, versus placebo, levodopa,
or both, with all other aspects of treatment being the same in
both arms. We defined early disease as patients with idiopathic
Parkinson’s disease who had no history of motor complications
and were untreated or had received limited (generally less than
12 months) exposure to antiparkinsonian drugs.
Outcome measures
Two independent reviewers extracted outcome data, which were
validated by a third reviewer, with any discrepancies resolved by
consensus. Data extracted included mortality; clinician rated dis-
ability scales, such as the unified Parkinson’s disease rating scale;
need for levodopa; incidence of motor complications; side
effects; and withdrawal of patients from the trial. We used
outcome data at the longest available follow up, other than for
unified Parkinson’s disease rating scale data, which we analysed
at three months after randomisation (except for two studies, for
One extra table and four extra figures are on bmj.com
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which we used data at one month and six weeks). Although pub-
lished scores only give a crude idea of quality, two investigators
independently scored the methodological quality of the included
studies.
Statistical analysis
We combined results of each trial by using standard
meta-analytic methods to estimate an overall treatment effect for
MAOBI versus non-MAOBI treated patients. We subclassified
trials according to the randomised treatment comparison:
MAOBI versus placebo; MAOBI+levodopa (LD) versus
placebo+LD or MAOBI+LD versus LD (classified as MAOBI+LD
versus LD); and MAOBI versus LD.We used tests of heterogene-
ity to assess for differences in treatment effects between trials and
subgroups of trials.8
For event data (such as mortality) we obtained estimates of
the treatment effects for most trials from the number of events
reported in each arm and used the methods of Mantel and
Haenszel to combine them.9 10 This involved comparing the
number of events observed with the number of events that would
have been expected if the probability of that event was unrelated
to treatment. For each trial we calculated the “observed minus
expected” difference and its variance. Summing these statistics
for each trial provided the overall statistics that we used to calcu-
late odds ratios with 95% confidence intervals.8 11 However, if a
hazard ratio, odds ratio, relative risk, or odds reduction, plus a
confidence interval or a P value, was available then we used this
information to obtain a more accurate estimate of the treatment
effect.12
For continuous variables (such as clinician rated disability
scales), we used weighted mean difference methods.13 For each
trial we calculated the difference (and its variance) between the
means of the outcome measure for each treatment group. We
combined these values to give the overall weighted mean differ-
ence and its standard error, with 95% confidence interval, for this
pooled estimate of the mean difference.
Results
Trials and patients
We identified 18 randomised trials of MAOBI treatment in early
Parkinson’s disease. (See fig A on bmj.com for QUORUM state-
ment flow diagram.) We excluded one crossover study, as the trial
did not provide data split by treatment period.14 We therefore
included 17 trials involving 3525 patients in this meta-analysis
(table 1 and table on bmj.com).4 15–36 Thirteen trials were of
selegiline, three were of lazabemide, and one was of rasagiline.
Duration of treatment varied from six weeks to 10 years; shorter
trials assessed symptomatic control and tolerability, and longer
trials assessed disease progression and mortality. One trial
contributed data to more than one comparison (MAOBI v
placebo and MAOBI+LD v LD).24 In the UK-PDRG study,
patients who had inadequate symptom control or were unable to
tolerate their original allocation to the dopamine agonist
bromocriptine were re-randomised to selegiline plus levodopa
or levodopa alone.4
Table 2 shows the methodological quality of the included tri-
als. Ten trials described the method of randomisation used
(blocking, random number generator, computer); only four trials
clearly had an adequate concealment of allocation procedure (by
virtue of a central randomisation service). All trials provided
information on blinding (15/17 trials were double blind), and all
trials reported follow up data, although some trials did not
include all randomised patients in the final analyses despite
claiming to have used an intention to treat analysis.
Mortality
Mortality data were available from nine trials of selegiline and
one of lazabemide (fig 1). We considered the UK-PDRG study,
which initially reported 76/271 (28%) deaths in the selegiline
arm compared with 44/249 (18%) deaths in the levodopa arm
(odds ratio 1.57, 95% confidence interval 1.09 to 2.30; P = 0.015)
to be hypothesis generating.4 In the other trials, which we treated
as confirmatory studies, no excess of deaths occurred with
MAOBI compared with the control arm (15.5% v 18.2% deaths;
odds ratio 1.02, 0.84 to 1.25; P = 0.8). Taking all available data,
287 (20%) deaths occurred in 1436 MAOBI patients compared
with 257 (21%) in 1215 control patients (odds ratio 1.13, 0.94 to
1.34; P = 0.2). We found no significant heterogeneity between tri-
als (P = 0.6), even including the UK-PDRG study.
Clinical disability rating scales
Data from rating scales were available from only six trials of sel-
egiline.15 19 24 26 27 32 Unified Parkinson’s disease rating scale scores
at three months were 2.7 (95% confidence interval 1.4 to 4.1;
P = 0.00009), 1.8 (0.8 to 2.7; P = 0.0004), and 0.9 (0.5 to 1.4;
P = 0.00007) points better with selegiline than with control for
total score, motor score, and activities of daily living score (see
figs B-D on bmj.com). The large DATATOP study accounted for
more than 65% of the patients analysed and more than 79% of
patients in the MAOBI versus placebo comparison.32 However,
combined results from the other two studies of MAOBI versus
placebo were consistent with those from DATATOP and
independently significant (P = 0.004).15 19
Need for levodopa
For the 12 trials comparing an MAOBI with placebo, data on the
need for levodopa were available from eight studies with a
median follow up of 13 months (range 3 months to 5
years).19–23 26 31 33 A highly significant reduction in the need for
levodopa occurred in patients randomised to an MAOBI
compared with those on placebo (odds ratio 0.57, 0.48 to 0.67;
P < 0.00001; fig 2). For trials comparing selegiline and levodopa
with levodopa alone, adequate data on dose of levodopa for
meta-analysis were available from two trials.24 27 The dose of levo-
dopa needed for adequate symptom control was 67 (14 to 119;
P = 0.01) mg lower in the selegiline arm.
Motor complications
Data on motor complications were available from five
trials.25 27 28 30 35 A 25% reduction in motor fluctuations occurred
in patients randomised to an MAOBI (odds ratio 0.75, 0.59 to
0.95; P = 0.02; fig 3). However, we found no difference in the
incidence of dyskinesia between the MAOBI and non-MAOBI
groups (odds ratio 0.97, 0.75 to 1.26; P = 0.8; fig 3). We found no
evidence of heterogeneity between the trials or the three
treatment comparisons for either outcome.
Side effects and withdrawals
More side effects were reported in patients randomised to an
MAOBI, which was of borderline significance (odds ratio 1.36,
1.02 to 1.80; P = 0.04). Data on specific side effects were rarely
reported, so any subanalysis of these data is of limited value.
More MAOBI patients than non-MAOBI patients withdrew
owing to adverse events (odds ratio 2.16, 1.44 to 3.23; P = 0.0002;
fig 4), with some evidence of heterogeneity between trials
(P = 0.03) but not between the three treatment comparisons
(P = 0.09). This heterogeneity was explained by the atypical
results in the UK-PDRG study, which reported significantly more
dropouts due to adverse events in the open label selegiline plus
levodopa arm than with levodopa alone (14% v 3%). In contrast,
significantly more patients were withdrawn from this trial in the
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levodopa arm owing to protocol violations (1% v 15%); 28/37
patients were withdrawn following the introduction of selegiline
to their treatment regimen after publication of the DATATOP
trial results. An analysis of the data on dropouts due to adverse
events for placebo controlled trials only (that is, excluding the
UK-PDRG and Italy studies) showed no difference between
MAOBI and non-MAOBI patients (odds ratio 1.52, 0.87 to 2.68;
P = 0.1), with no evidence of heterogeneity between trials
(P = 0.2) or between the two treatment comparisons (P = 0.9).
We found no difference between the two groups (MAOBI v
non-MAOBI) in the overall numbers of patients withdrawing
from the trials (18% v 19%; odds ratio 1.06, 0.87 to 1.28; P = 0.6).
However, patients withdrew from different trials for quite varied
reasons—such as lack of efficacy, toxicity, patients given selegiline
by their general practitioners after publication of the DATATOP
study—and this is reflected in the significant heterogeneity
between trials (P = 0.007), making it difficult to interpret overall
withdrawal rates.
Discussion
This is the first systematic review to assess MAOBIs as a drug
class in early Parkinson’s disease and the most comprehensive in
the range of outcomes assessed. It provides the most reliable
available summary of the current evidence from clinical trials of
MAOBIs in the treatment of early Parkinson’s disease and clari-
fies previous uncertainties about the role of these drugs.
One fundamental objective was to investigate whether MAO-
BIs, and selegiline in particular, increase mortality in patients
with Parkinson’s disease, as suggested by the UK-PDRG trial.4
Our systematic review provides evidence to refute this
hypothesis; no increase in mortality was seen in the other trials,
either individually or in the pooled data, or in subsequent follow
up of the UK-PDRG trial.35 It therefore seems likely that the early
excess of deaths in the selegiline arm of the UK-PDRG study
compared with the levodopa arm was a chance finding, although
the confidence interval reported in this review is compatible with
a small increase, or indeed decrease, in mortality.
Our systematic review also shows that early use of selegiline
delays the need for levodopa and that when selegiline is given
Table 1 Characteristics of trials of monoamine oxidase type B inhibitors included in meta-analysis
Trial Comparison* No. randomised (MAOBI/control)
Treatment period (length of follow
up†) Outcome data reported‡
Short term tolerability trials
Hungary-Scotland15 Selegiline v placebo 20 (10/10) 6 weeks Disability, dropouts
PSG lazabemide 116 Lazabemide v placebo 201 (150/51) 4 or 6 weeks then washout (8
weeks)
Tolerability, disability, side effects,
dropouts
PSG lazabemide 217 Lazabemide+LD v placebo+LD 137 (105/32) 4 or 6 weeks then washout (8
weeks)
Tolerability, disability, side effects,
dropouts
Italy-Germany18 Selegiline+lisuride v placebo+lisuride 20 (10/10) 3 months Disability, lisuride dose, dropouts
Longer term efficacy trials
France19 Selegiline v placebo 93 (48/45) 3 months Disability, need for LD, side effects,
dropouts
PSG TEMPO20 Rasagiline v placebo 404 (266/138) 6 months Disability, need for LD, side effects,
dropouts
Swedish PSG21 Selegiline (±LD) v placebo (±LD) 157 (81/76) 12 months† (need for LD at 60
months)
Need for LD, disability, mortality,
dropouts
UK Middlesex22 Selegiline v placebo 30 (14/16) 54 weeks or until LD Disability, need for LD, mortality,
side effects, dropouts
PSG lazabemide 323 Lazabemide v placebo 321 (255/66) 52 or 54 weeks or until LD, then
washout
Need for LD, disability, side effects,
dropouts
USA (bromocriptine)24 Selegiline+bromocriptine v
placebo+bromocriptine
52 (27/25) 14 months Disability, mortality, LD dose,
dropouts
USA (levodopa)24 Selegiline+LD v placebo+LD 49 (25/24) 14 months Disability, mortality, LD dose,
dropouts
Italy25 Selegiline (±LD) v LD 332 (166/166) Median=34 months† Motor complications, mortality,
dropouts
California26 Selegiline v placebo 54 (27/27) 3 years or until LD, then washout Need for LD, disability, side effects,
dropouts
Norway-Denmark27 Selegiline+LD v placebo+LD 163 (77/86) 5 years Disability, motor complications,
mortality, LD dose, side effects,
dropouts
SELEDO28 Selegiline+LD v placebo+LD 116 (61/55) 5 years Time to 50% increase in LD dose,
disability, mortality, motor
complications, side effects, dropouts
Finland29-31 Selegiline (±LD) v placebo (±LD) 56 (52 analysed) (28/28) Approximately 6 years† (need for LD
at 4 years)
Need for LD, LD dose, disability,
motor complications, mortality,
dropouts
DATATOP32-34 Selegiline v placebo (until LD
needed)§ (± tocopherol in each arm)
800 (399/401) Mean=8.2 years† (need for LD and
dropouts at mean 14 months)
Need for LD, disability, mortality,
dropouts
UK-PDRG4 35 36 Selegiline + LD v LD (until selegiline
arm closed)
520 (271/249) 10 years (dropouts at approximately
6 years)
Mortality, disability, LD dose, motor
complications, dropouts
LD=levodopa; MAOBI=monoamine oxidase type B inhibitor.
*±LD indicates that trial design allowed levodopa to be added to the randomised treatment.
†In all cases the length of follow up equalled the planned treatment period, except for the Swedish PSG study in which 7 years’ treatment was planned. In the Finland study, patients were on
monotherapy (selegiline v placebo) for approximately 1.2 years then followed for 5 years on combination treatment. For the Italy and DATATOP studies, median and mean lengths of follow up
were stated.
‡Not all outcome data reported were available for meta-analysis. Disability refers to clinician rated disability scales (such as unified Parkinson’s disease rating scale, Hoehn and Yahr, Webster).
§Study closed early and 310 patients who had not reached endpoint were treated with open label selegiline.
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concomitantly with levodopa lower doses of levodopa are
needed. This may be due to symptomatic relief from selegiline:
total scores, motor scores, and activities of daily living scores on
the unified Parkinson’s disease rating scale were significantly bet-
ter with selegiline than with placebo in the first three months of
treatment. (The lack of apparent benefit from selegiline when
added to levodopa or bromocriptine is probably explained by
adjustments in the dose of the concomitant drug.) However,
whether the benefits seen are large enough to be clinically
important is debatable. Avoiding exposure to levodopa should
reduce the risk of developing motor complications, which are
believed to be a consequence of long term use of levodopa. In
the few studies that reported these data, fewer selegiline patients
developed motor fluctuations. Interestingly, no reduction in dys-
kinesia was observed, although a benefit cannot be excluded
given the wide confidence intervals. The reduction in motor fluc-
Table 2 Methodological quality of included studies
Trial Randomisation* Concealment of allocation† Blinding‡ Follow up§
Short term tolerability trials
Hungary-Scotland15 1 0 1 2
PSG lazabemide 116 1 0 1 2
PSG lazabemide 217 1 0 1 2
Italy-Germany18 1 0 1 2
Long term efficacy trials
France19 2 0 1 1
PSG TEMPO20 1 0 1 2
Swedish PSG21 1 0 1 1
UK Middlesex22 1 0 1 1
PSG lazabemide 323 2 0 1 2
USA24 2 0 1 1
Italy25 2 1 0 1
California26 2 0 1 1
Norway-Denmark27 2 1 1 1
SELEDO28 2 0 1 1
Finland29-31 2 0 1 1
DATATOP32-34 2 1 1 2
UK-PDRG4 35 36 2 1 0 2
*0=none; 1=yes, method used not given; 2=yes, method used given (blocking, random numbers, computer generated lists).
†0=none, not stated, or not clear; 1=yes.
‡0=no; 1=yes (double blind).
§0=none reported; 1=reported, data not analysed according to intention to treat; 2=reported, data analysed according to intention to treat.
0.5 1.0
Effect 2P=0.2
1.5 2.0
Favours placebo/LDFavours MAOBI 
0
Odds ratio
(95% CI)
Hypothesis generating report
UK-PDRG 19954
Subsequent data
Swedish PSG21
UK Middlesex22
PSG Lazabemide 323
USA (Bromocriptine)24
USA (Levodopa)24
Italy25
California26
Norway-Denmark27
SELEDO28
Finland31
DATATOP34
UK-PDRG*35
UK-PDRG (RR)36
Subtotal
Test for heterogeneity: χ2=6.6, df=11, P=0.8
Total
Test for heterogeneity (13 trials): χ2=10.5, df=12, P=0.6
Test for heterogeneity between subtotals: χ2=3.9, df=1, P=0.05
76/271
3/81
0/14
4/255
2/27
1/25
25/154
4/73
2/59
7/27
70/399
72/195
21/51
211/1360
287/1436
44/249
3/76
2/16
2/66
5/25
1/24
25/149
                  Data not available
4/81
3/50
6/25
67/401
74/205
21/53
213/1171
257/1215
12.4
-0.1
-0.9
-0.8
-1.6
0
-0.4
0.2
-0.7
0.3
1.7
0.3
4.3
2.2
14.6
27.6
1.5
0.5
1.0
1.5
0.5
10.5
1.9
1.2
2.5
28.4
36.6
10
95.9
123.5
1.57 (1.09 to 2.30)
2P=0.015
0.94 (0.18 to 4.77)
0.14 (0.01 to 2.42)
0.45 (0.06 to 3.32)
0.35 (0.07 to 1.68)
0.96 (0.06 to 15.80)
0.96 (0.52 to 1.76)
1.12 (0.27 to 4.62)
0.55 (0.09 to 3.33)
1.11 (0.32 to 3.84)
1.06 (0.73 to 1.53)
1.01 (0.73 to 1.40)
1.54 (0.83 to 2.87)
1.02 (0.84 to 1.25)
2P=0.8
1.13 (0.94 to 1.34)
MAOBITrials Placebo/LD
Death/patients Statistics
(O-E) Variance
Fig 1 Mortality in trials of monoamine oxidase type B inhibitors. (LD=levodopa; MAOBI=monoamine oxidase type B inhibitor; O-E=observed minus expected;
RR=re-randomisation data from UK-PDRG. *Data from subsequent follow up of UK-PDRG trial—patients counted only once in total denominator)
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tuations could be due to lower exposure to levodopa or to a neu-
roprotective effect of selegiline. A reduction in motor
complications has also been observed with dopamine agonists,
the other levodopa sparing agents commonly used in early Par-
kinson’s disease,37 and similar uncertainties exist about the
mechanisms underlying this observation.
Our review provides no evidence that mortality is increased
by selegiline and suggests that this inexpensive drug could be
one of the most clinically effective and cost effective treatments
available for early Parkinson’s disease. However, despite promis-
ing clinical trial results, use of selegiline in the United Kingdom
dropped substantially after the UK-PDRG report of increased
mortality.4 Data on the other MAOBIs, lazabemide and
rasagiline, are consistent with those seen with selegiline, but the
limited information available makes any conclusions on the role
of MAOBIs as a class difficult.
The review also highlights the lack of data on the long term
balance of benefits and risks of MAOBIs. A lack of trials that
directly compare active treatments (for example, MAOBI versus
dopamine agonists), as well as poor reporting of results in many
trials, short term follow up, and a lack of patient rated quality of
life data, limits the interpretation and applicability of these
results. To determine more reliably the role of MAOBIs in early
Parkinson’s disease, further large, well designed randomised tri-
als that evaluate the long term balance of benefit and harm,
comparing MAOBIs with other active agents, such as dopamine
agonists and levodopa, are urgently needed—for example, the
PD MED trial (www.pdmed.bham.ac.uk (accessed 22 Jun 2004)).
This can be achieved by using patient rated quality of life scales,
such as the Parkinson’s disease questionnaire (PDQ-39), which
assess all aspects of the patient’s life and are sensitive to changes
that are meaningful to patients, as the main outcome measure.38
We recognise the work of all the original trial teams and the people who did
the trials that contributed to this meta-analysis, and we thank the patients
who agreed to help future patients by taking part in these trials.
MAOBI v placebo
France19
PSG TEMPO*20
PSG Lazabemide 323
UK Middlesex22
DATATOP33
California†26
Finland†31
Swedish PSG†21
Total
Test for heterogeneity (8 trials): χ2=9.5, df=7, P=0.2
Median length of follow up=13 months (mean=24 months)
Trials
3 months
6 months
52 weeks
54 weeks
14 months
3 years
4 years
5 years
Length of
follow up
0.25 (0.06 to 0.98)
0.80 (0.45 to 1.43)
0.57 (0.32 to 1.01)
2.64 (0.45 to15.39)
0.50 (0.38 to 0.66)
0.39 (0.21 to 0.71)
0.52 (0.29 to 0.94)
0.69 (0.50 to 0.96)
0.57 (0.48 to 0.67)
2/44
37/266
80/255
4/14
155/399
21/26
23/27
72/81
394/1112
7/38
23/138
29/66
2/16
225/401
22/25
21/25
69/76
398/785
-2.8
-2.5
-6.6
1.2
-34.5
-10.1
-7.2
-13.1
-75.6
2.0
11.5
11.8
1.2
49.9
10.8
11.0
35.2
133.5
MAOBI Placebo
LD/patients Statistics
(O-E) Variance
0.5 1.0
Effect 2P<0.00001
1.5 2.0
Favours placeboFavours MAOBI 
0
Odds ratio
(95% CI)
Fig 2 Need for levodopa treatment in trials comparing monoamine oxidase type B inhibitors and placebo. (O-E=observed minus expected; LD=levodopa;
MAOBI=monoamine oxidase type B inhibitor. *Rasagiline. †O-E and variance based on published time to event analyses)
Motor fluctuations*
Finland30
Norway-Denmark27
SELEDO28
UK-PDRG35
Italy25
Subtotal
Test for heterogeneity between subgroups: χ2=2.7, df=2, P=0.3
Dyskinesia
Norway-Denmark27
UK-PDRG35
Italy25
Subtotal
Test for heterogeneity between subgroups: χ2=0.9, df=1, P=0.3
Motor complication
Odds ratio
(95% CI)
MAOBI v placebo
MAOBI+LD v LD
MAOBI+LD v LD
MAOBI+LD v LD
MAOBI v LD
MAOBI+LD v LD
MAOBI+LD v LD
MAOBI v LD
Treatment comparison
(subgroup)
0.46 (0.13 to 1.67)
0.50 (0.25 to 1.02)
0.67 (0.23 to 1.91)
1.03 (0.73 to 1.46)
0.60 (0.40 to 0.90)
0.75 (0.59 to 0.95)
2P=0.02
1.00 (0.48 to 2.07)
1.06 (0.75 to 1.50)
0.80 (0.50 to 1.29)
0.97 (0.75 to 1.26)
2P=0.8
5/23
17/65
7/61
161/271
29/155
219/575
18/73
150/271
32/155
200/499
8/21
30/72
9/55
146/249
46/156
239/553
20/81
134/249
42/156
196/486
-1.8
-5.3
-1.4
1.0
-11.9
-19.4
0
2.0
-3.8
-1.8
2.3
7.8
3.5
31.4
23.4
68.4
7.2
32.2
16.8
56.2
MAOBI Placebo/LD
Motor comp/patients Statistics
(O-E) Variance
0.5 1.0 1.5 2.0
Favours placebo/LDFavours MAOBI 
0
Fig 3 Incidence of motor complications in trials of monoamine oxidase type B inhibitors. (O-E=observed minus expected; LD=levodopa; MAOBI=monoamine oxidase
type B inhibitor. *Motor fluctuations defined as on-off or end of dose fluctuations, wearing off, or random oscillations)
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